Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A bispecific antibody triple threat for myeloma. Extended follow-up from the phase 1b CAMMA 1 trial shows that cevostamab plus pomalidomide and dexamethasone delivers high response rates and durable remissions in BCMA-naive relapsed/refractory multiple myeloma. With neither median PFS nor duration of response reached at ~20 months, the 70-mg regimen with triple step-up dosing has been selected for the phase 3 CEVOLUTION trial.
A bispecific antibody combo is making waves in myeloma treatment. Extended follow-up data from the phase 1b CAMMA 1 trial, presented at the 23rd International Myeloma Society Annual Meeting, show that cevostamab — an FcRH5×CD3 T-cell–engaging bispecific antibody — combined with pomalidomide and dexamethasone (pom-dex) produces deep, durable responses in patients with BCMA-naive relapsed/refractory multiple myeloma (RRMM). Responses deepened over time, and most patients who achieved a complete response also tested negative for measurable residual disease (MRD).
The safety picture also improved with a smarter dosing approach. Triple step-up dosing significantly reduced the incidence and severity of cytokine release syndrome (CRS) compared to double step-up dosing, without sacrificing efficacy. Notably, unlike BCMA-targeted bispecifics, this regimen did not cause a persistent drop in polyclonal IgG levels, suggesting preserved immune function.
By the Numbers:
Why it matters: These results support the 70-mg cevostamab plus pom-dex regimen with triple step-up dosing as the recommended phase 3 dose, now being tested head-to-head against standard-of-care in the ongoing CEVOLUTION trial — a potentially practice-changing step for patients with RRMM.
